甲磺酸贝舒地尔片在中国上市了吗?好购买吗？

Introduction: Besudil mesylate tablets belong to the serine/threonine kinase inhibitor class of drugs and are suitable for the treatment of patients aged 12 years and above suffering from chronic graft-versus-host disease and who have failed at least two systemic therapies.

Besudil mesylate tablets can cause clinical improvement in 75% of patients. Most responses are partial, but usually provide sufficient relief of signs and symptoms to improve quality of life and reduce the need for further treatment.

Are Besudil Mesylate Tablets on the market in China?

It is on the market in China. On August 3, 2023, the official website of China's National Medical Products Administration (NMPA) recently announced that Yehui Pharmaceutical's marketing application for ROCK2 inhibitor besudil mesylate tablets has been approved for the treatment of chronic graft-versus-host disease (cGVHD), and has also been included in medical insurance and enjoys medical insurance reimbursement.

Is Besudil mesylate tablets easy to buy?

Besudil mesylate tablets are easy to buy. You can choose from the following types.

1. Hospital pharmacy: Patients can go to the local hospital for treatment. After the doctor issues a prescription, they can purchase Besudil mesylate tablets directly in the pharmacy.

2. Legal pharmacies: Some legal large pharmacies or professional pharmacies may sell besudil mesylate tablets. Patients can consult several physical pharmacies.

3. Online pharmacies: Some legitimate online pharmacies may provide sales services for besudil mesylate tablets. After placing an order, the drug is usually obtained by mail.

Usage of Besudil Mesylate Tablets in Special Populations

1. Children: The safety and effectiveness of Besudil Mesylate Tablets for children under 12 years of age have not yet been determined, and use by children under 12 years of age is not recommended.

2. Elderly people: In the clinical study of Besudil Mesylate Tablets, 26% of 186 patients with chronic GVHD were 65 years old and above. There are no clinically meaningful differences in the safety or effectiveness of besudil mesylate tablets compared with younger patients.

3. Patients with renal insufficiency: Besudil mesylate tablets have not been studied in patients with severe renal insufficiency. For patients with severe renal insufficiency, the risks and potential benefits should be considered before starting treatment with besudil mesylate tablets.

Besudil mesylate tablets are an oral small molecule inhibitor that inhibits rho-related coiled-coil protein kinase and is used to treat refractory chronic graft-versus-host disease. Treatment results in transient, usually mild, elevations in serum aminotransferase levels, but has not been associated with clinically apparent cases of acute liver injury.